Dataset Information


Expression profile after stable HIF-1a inhibition in gastric cancer cells under normoxic conditions

ABSTRACT: Based on the results of numerous clinical and preclinical analyses, the transcription factor HIF-1a has been identified as an important tumor-promoting factor and is considered to be an attractive target for cancer therapy. To further deconstruct the molecular nature of HIF-1a’s role in tumorigenesis, we have applied lentiviral shRNA transduction to establish HIF-1a-deficient gastric cancer cells. Interestingly, functional analyses failed to show a significant growth defect of HIF-1a-deficient gastric cancer cells in vitro and in vivo. These observations led us to propose that stable inactivation of HIF-1a resulted in efficient compensation enabling cell growth and, ultimately, tumor progression in a HIF-1a-independent manner. To better understand the mechanisms that control this compensation, we performed transcriptomics of control (“scrambled” (SCR)) and HIF-1a-deficient (HIF) gastric cancer cells. Analysis of hypoxia-inducible factor-1alpha (HIF-1a)-deficient gastric cancer cells under normoxia. The transcription factor HIF-1a is a key regulator of oxygen homeostasis and has been identified as an important tumor-promoting factor. Results provide insight into the role of HIF-1a in gastric carcinogenesis. Overall design: Gastric cancer AGS cells were lentiviral and stably transduced with a small hairpin RNA targeting human HIF-1a or a control shRNA. RNA was extracted from control and HIF-1a-deficient cells. Each cell line was analyzed in triplicate for a total of six samples.

INSTRUMENT(S): Illumina HumanRef-8 v3.0 expression beadchip

SUBMITTER: Nadine Rohwer  

PROVIDER: GSE57200 | GEO | 2017-02-11



altmetric image


Despite the approval of numerous molecular targeted drugs, long-term antiproliferative efficacy is rarely achieved and therapy resistance remains a central obstacle of cancer care. Combined inhibition of multiple cancer-driving pathways promises to improve antiproliferative efficacy. HIF-1 is a driver of gastric cancer and considered to be an attractive target for therapy. We noted that gastric cancer cells are able to functionally compensate the stable loss of HIF-1α. Via transcriptomics we ide  ...[more]

Similar Datasets

2018-09-12 | GSE119775 | GEO
2019-11-18 | BIOMD0000000867 | BioModels
2011-10-23 | E-GEOD-29988 | ArrayExpress
2014-05-14 | E-GEOD-55915 | ArrayExpress
2015-07-10 | E-GEOD-67237 | ArrayExpress
2010-07-13 | GSE18478 | GEO
2010-07-13 | E-GEOD-18478 | ArrayExpress
2013-12-31 | E-GEOD-41999 | ArrayExpress
2007-01-12 | GSE6091 | GEO
| GSE103519 | GEO